Skip to main content

Table 3 Distribution of bleeding characteristics of all included hemorrhages

From: Impaired kidney function at ED admission: a comparison of bleeding complications of patients with different oral anticoagulants

 

DOAC (n = 158)

VKA (n = 419)

Total (n = 577)

p

Location, [n (%)]a

 Epistaxis

14 (8.9)

46 (11.0)

60 (10.4)

0.457

 Oral

2 (1.3)

8 (1.9)

10 (1.7)

0.597

 Intracranial

23 (14.6)

94 (22.4)

117 (20.3)

0.036

 Thorax

5 (3.2)

8 (1.9)

13 (2.3)

0.365

 Extremity

1 (0.6)

0 (0.0)

1 (0.2)

0.103

 Gastrointestinal

55 (34.8)

119 (28.4)

174 (30.2)

0.135

 Intraabdominal

3 (1.9)

5 (1.2)

8 (1.4)

0.518

 Retroperitoneal

1 (0.6)

10 (2.4)

11 (1.9)

0.170

 Superficial

26 (16.5)

77 (18.4)

103 (17.9)

0.591

 Intraocular

0 (0.0)

2 (0.5)

2 (0.3)

0.384

 Intraarticular

1 (0.6)

6 (1.4)

7 (1.2)

0.434

 Intraspinal

1 (0.6)

1 (0.2)

2 (0.3)

0.472

 Intramuscular

4 (2.5)

25 (6.0)

29 (5.0)

0.092

 Gross haematuria

18 (11.4)

34 (8.1)

52 (9.0)

0.220

 Haemoptysis

3 (1.9)

7 (1.7)

10 (1.7)

0.851

 Other location

22 (13.9)

41 (9.8)

63 (10.9)

0.155

Extent of bleeding, [n (%)]

 Haemorrhagic shock

10 (6.3)

21 (5.0)

31 (5.4)

0.531

 Major bleeding

67 (42.4)

183 (43.7)

250 (43.3)

0.784

  1. Abbreviation: DOAC direct oral anticoagulants, VKA Vitamin-K antagonist
  2. a the study population is by definition made of patients admitted for major hemorrhage, thus less frequent occurrence of one variable might be caused by a higher frequency of another variable and vice versa